Camphor

Camphor

SCHEMBL285280

CC1(C)[C@H]2CC[C@@]1(C)C(=O)C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 1.00
KMT2A Q03164 4/20 1.00
MEN1 O00255 3/20 1.00
MAPT P10636 2/20 1.00
LMNA P02545 1/20 1.00
L3MBTL1 Q9Y468 1/20 0.52
PTPN1 P18031 1/20 0.41
F2 P00734 2/20 0.41
PRSS1 P07477 2/20 0.41
PRSS2 P07478 2/20 0.41
PRSS3 P35030 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
HTT P42858 1/20 0.38
TP53 P04637 1/20 0.38
POLB P06746 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
KDM4E B2RXH2 1/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Camphor SCHEMBL31059217 1.00 ALDH1A1 (1.00) ALDH1A1KMT2AMEN1MAPTLMNA
Camphor SCHEMBL16068 1.00 ALDH1A1 (1.00) ALDH1A1KMT2AMEN1MAPTLMNA
Camphor SCHEMBL1151878 1.00 ALDH1A1 (1.00) ALDH1A1KMT2AMEN1MAPTLMNA
Camphor SCHEMBL1712401 1.00 ALDH1A1 (1.00) ALDH1A1KMT2AMEN1MAPTLMNA
Camphor SCHEMBL16582770 1.00 ALDH1A1 (1.00) ALDH1A1KMT2AMEN1MAPTLMNA
Camphor SCHEMBL13248606 1.00 ALDH1A1 (1.00) ALDH1A1KMT2AMEN1MAPTLMNA
Camphor SCHEMBL15542393 1.00 ALDH1A1 (1.00) ALDH1A1KMT2AMEN1MAPTLMNA
(-)-Camphor SCHEMBL1701376 1.00 ALDH1A1 (1.00) ALDH1A1KMT2AMEN1MAPTLMNA
Camphor SCHEMBL2037672 1.00 ALDH1A1 (1.00) ALDH1A1KMT2AMEN1MAPTLMNA
Camphor SCHEMBL29673264 1.00 ALDH1A1 (1.00) ALDH1A1KMT2AMEN1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12635710-B2 Methods of using formaldehyde-free antimicrobial compositions in animal by-product compositions EASTMAN CHEMICAL COMPANY (US) 2026-05-26 US claimed
US-12296042-B2 Cosmetic compositions comprising silicone elastomer CONOPCO, INC. (US) 2025-05-13 US claimed
EP-3908250-B1 COSMETIC COMPOSITIONS COMPRISING SILICONE ELASTOMER UNILEVER IP HOLDINGS B V (NL) 2025-03-26 EP claimed
US-20240327418-A1 MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR OCEAN UNIVERSITY OF CHINA (CN) 2024-10-03 US claimed
CN-118638123-A Camphor inner sulfonamide reversible phase change material and preparation method thereof 南昌大学 2024-09-13 CN claimed
US-20240215608-A1 METHODS OF USING FORMALDEHYDE-FREE ANTIMICROBIAL COMPOSITIONS IN ANIMAL BY-PRODUCT COMPOSITIONS EASTMAN CHEMICAL COMPANY (US) 2024-07-04 US claimed
EP-4319559-A1 METHODS OF USING FORMALDEHYDE-FREE ANTIMICROBIAL COMPOSITIONS IN ANIMAL BY-PRODUCT COMPOSITIONS Eastman Chemical Company (US) 2024-02-14 EP claimed
EP-4257663-A1 FOOD CONTACT SURFACE SANITIZING LIQUID The Procter & Gamble Company (US) 2023-10-11 EP claimed
WO-2022217031-A1 METHODS OF USING FORMALDEHYDE-FREE ANTIMICROBIAL COMPOSITIONS IN ANIMAL BY-PRODUCT COMPOSITIONS EASTMAN CHEMICAL COMPANY (US) 2022-10-13 WO claimed
EP-4040979-A1 ANTIMICROBIAL COMPOSITION FOR ANIMAL FEED Taminco BV (BE) 2022-08-17 EP claimed
US-20220079869-A1 COSMETIC COMPOSITIONS COMPRISING SILICONE ELASTOMER CONOPCO, INC., D/B/A UNILEVER (US) 2022-03-17 US claimed
EP-1894603-B1 Encapsulation of bulky fragrance molecules TAKASAGO PERFUMERY CO LTD (JP) 2014-11-19 EP claimed
US-12635710-B2 Methods of using formaldehyde-free antimicrobial compositions in animal by-product compositions EASTMAN CHEMICAL COMPANY (US) 2026-05-26 US disclosed
US-20260102359-A1 COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION ERESINA LLC (US) 2026-04-16 US disclosed
US-12600926-B2 Treatment compositions with modified amino acid dimers for delivering a benefit agent THE PROCTER & GAMBLE COMPANY (US) 2026-04-14 US disclosed
CN-120713838-B Medicinal injection and preparation method thereof 广东粤和泽药物研究有限公司 2026-03-03 CN disclosed
WO-2007038524-A2 COCRYSTALLIZATION METHODS SSCI, INC. (US) 2007-04-05 WO disclosed
CN-1846758-A Hypoglycemic medicine for treating diabetes and its prepn process RENMIN HOSPITAL YIAGCHENG HUBE (CN) 2006-10-18 CN disclosed
US-5268492-A Optically active diphosphines, intermediates thereof, and processes for production thereof MITSUI TOATSU CHEMICALS, INC. (JP) 1993-12-07 US disclosed
EP-0530015-A1 Optically active diphosphines, intermediates thereof, and processes for production thereof MITSUI TOATSU CHEMICALS, Inc. (JP) 1993-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12296042-B2 Cosmetic compositions comprising silicone elastomer CUTA, ERCC1, MMS19 ALDH1A1 230/4885KMT2A 1645/4885MEN1 660/4885
US-12600926-B2 Treatment compositions with modified amino acid dimers for delivering a benefit agent F2, C9, S100A8 ALDH1A1 2233/4885KMT2A 3763/4885MEN1 3507/4885
US-20220079869-A1 COSMETIC COMPOSITIONS COMPRISING SILICONE ELASTOMER CUTA, ERCC1, MMS19 ALDH1A1 230/4885KMT2A 1645/4885MEN1 660/4885
US-12635710-B2 Methods of using formaldehyde-free antimicrobial compositions in animal by-product compositions FABP2, FABP1, VIP ALDH1A1 1928/4885KMT2A 3786/4885MEN1 3600/4885
US-20240327418-A1 MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR HDAC3, HDAC1, HDAC11 ALDH1A1 380/4885KMT2A 138/4885MEN1 3861/4885
US-20260102359-A1 COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION COL2A1, COLGALT1, PLOD3 ALDH1A1 568/4885KMT2A 1308/4885MEN1 4053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.